SDS Optic plans that the first partnering agreements will be signed at the turn of 2024 and 2025, Mateusz Sagan, chief operating & business officer of the company, informed. He estimates that the transition to the WSE from NewConnect may be realistic in spring 2024.
“We hope to start part II of the clinical trial after the holidays. We assume that the period of 6-8 months to carry out this part is very realistic. We have had our first meetings with the Clairfield team here and in the USA. We plan that the first partnering agreements will be signed at the turn of 2024 and 2025,” said Sagan during the GPW Innovation Day organized by GPW and CC Group. The ISBnews agency is the media partner of the event.
By the end of the second quarter of this year, wants to open an R&D center in the US, the team recruitment process is underway, he added.
“We focus on a mix of two commercialization options: selling the technology and developing the technology platform for other applications on our own. What amounts are involved? It is difficult to give specific amounts today, it is very difficult to estimate. When you look at the transaction value range, it is very wide,” Sagan pointed out.
SDS Optic is a company that develops the proprietary inPROBE technological platform for real-time medical diagnostics in cancer, infectious, viral, bacterial and fungal diseases. The company debuted on the NewConnect market in 2022.